glp 1 review GLP-1 receptor agonists show promise in treating substance use disorders Current Insights, Advantages and Challenges

Description

These inconsistencies may be due to the small sample size of the included studies, differences in baseline characteristics of study participants, differences in study design such as follow-up duration or control group, and other factors

By 2016, the GLP-1 toolbox for clinicians included twice-daily, once-daily, and once-weekly options, allowing tailoring to patient needs and preferences

Retrieved from Ko, J

H.GotesonA.GribbleF

Further reading on observed adverse signal profiles from the investigational phase 2 programme is available in the Retatrutide Side Effects: Detailed Guide with Clinical Trial Insights 2026 article, which summarises published tolerability data for research planning purposes